A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
MIMEDX is a pioneer and leader focused on helping humans heal. With nearly two decades of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. Since its inception, MIMEDX has focused on leading the industry with its deep expertise, unmatched peer-reviewed scientific and clinical data, robust intellectual property portfolio and an expansive library of real-world evidence supporting the use of our products. Historically, our sole focus has been on placental biologics.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 419M | 419M | 349M | 321M | 268M | 242M |
| Net Income | 49M | 49M | 42M | 58M | -30M | -16M |
| EPS | $0.32 | $0.32 | $0.28 | $0.37 | $-0.33 | $-0.15 |
| Free Cash Flow | 73M | 73M | 65M | 25M | -19M | -5.2M |
| ROIC | 42.6% | 20.8% | 1053.9% | 350.1% | -98.7% | -34.1% |
| Gross Margin | 82.6% | 82.6% | 82.8% | 83.0% | 82.0% | 83.6% |
| Debt/Equity | 0.08 | 0.08 | 0.10 | 0.35 | -2.70 | 587.46 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 64M | 64M | 59M | 37M | -15M | -7.1M |
| Operating Margin | 15.3% | 15.3% | 16.9% | 11.5% | -5.5% | -2.9% |
| ROE | 18.9% | 21.6% | 22.0% | 40.8% | - | -20025.6% |
| Shares Outstanding | 152M | 152M | 151M | 157M | 92M | 109M |
MIMEDX GROUP, INC. passes 4 of 9 quality checks, suggesting mixed fundamentals.
MIMEDX GROUP, INC. trades at 12.3x trailing earnings, compared to its 15-year median P/E of 23.3x, suggesting it is currently Cheap relative to its historical range. On a free-cash-flow basis, the stock trades at 8.0x vs a median of 22.9x. The company's 5-year average gross margin is 82.8%. At current prices, the estimated annualized return to fair value is +3.2%.
MIMEDX GROUP, INC. (MDXG) has a current P/E ratio of 12.3, compared to its historical median P/E of 23.3. The stock is currently considered Cheap based on its historical valuation range.
MIMEDX GROUP, INC. (MDXG) has a 5-year average return on invested capital (ROIC) of -37.3%. This is below average and may indicate limited pricing power.
MIMEDX GROUP, INC. (MDXG) has a market capitalization of $595M. It is classified as a small-cap stock.
MIMEDX GROUP, INC. (MDXG) does not currently pay a regular dividend.
Based on historical P/E analysis, MIMEDX GROUP, INC. (MDXG) appears cheap. The current P/E of 12.3 is 47% below its historical median of 23.3. The estimated fair value CAGR (P/E method) is 9.0%.
MIMEDX GROUP, INC. (MDXG) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
MIMEDX GROUP, INC. (MDXG) reported annual revenue of $419 million in its most recent fiscal year, based on SEC EDGAR filings.
MIMEDX GROUP, INC. (MDXG) has a net profit margin of 11.6%. This is a healthy margin.
MIMEDX GROUP, INC. (MDXG) generated $73 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
MIMEDX GROUP, INC. (MDXG) has a debt-to-equity ratio of 0.08. This indicates a conservatively financed balance sheet.
MIMEDX GROUP, INC. (MDXG) reported earnings per share (EPS) of $0.32 in its most recent fiscal year.
MIMEDX GROUP, INC. (MDXG) has a return on equity (ROE) of 21.6%. This indicates the company generates strong returns for shareholders.
MIMEDX GROUP, INC. (MDXG) has a 5-year average gross margin of 82.8%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 16 years of financial data for MIMEDX GROUP, INC. (MDXG), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
MIMEDX GROUP, INC. (MDXG) has a book value per share of $1.69, based on its most recent annual SEC filing.